
Apella is a technology company that provides the world's only real-time OR management platform. By integrating ambient technology, AI, and EHR data, Apella helps surgical teams stay on track throughout the day to serve more patients and go home on time. It offers real-time operational intelligence to eliminate delays and inefficiencies, improves case volume and revenue by 10%, and reduces average turnover time by 15% to enable more cases. The platform automates admin tasks to reduce staff burnout, saving an average of 36 overtime minutes per OR per month. Apella aims to drive healthcare outcomes with innovative teams by providing actionable insights and predictions based on real-time data.

Apella is a technology company that provides the world's only real-time OR management platform. By integrating ambient technology, AI, and EHR data, Apella helps surgical teams stay on track throughout the day to serve more patients and go home on time. It offers real-time operational intelligence to eliminate delays and inefficiencies, improves case volume and revenue by 10%, and reduces average turnover time by 15% to enable more cases. The platform automates admin tasks to reduce staff burnout, saving an average of 36 overtime minutes per OR per month. Apella aims to drive healthcare outcomes with innovative teams by providing actionable insights and predictions based on real-time data.
Product: Real-time operating-room (OR) management platform using ambient AI, computer vision, and EHR integration
Impact: Improves case volume (~+10%), reduces turnover time (~-15%), and saves staff overtime (avg 36 minutes/OR/month)
Scale: Deployed across hundreds of ORs and has supported hundreds of thousands of surgical cases
Funding: Raised a $21M Series A (2021) and an $80M Series B (announced Jan 2026); total funding reported ~$24M (as of 2023 data) and later Series B
Employees: Approximately 110
Perioperative operations and operating-room efficiency for hospitals and surgical teams
Health technology
$21,000,000
Announced Dec 22, 2021
$80,000,000
Announced Jan 7–8, 2026; round includes equity and venture debt
“Casdin Capital, Vensana Capital, PFM Health Sciences, Upside Partnership, Operator Partners, HighlandX, and other returning and new investors across rounds”